Cargando…
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics
Membrane transporters play a fundamental role in the tissue distribution of endogenous compounds and xenobiotics and are major determinants of efficacy and side effects profiles. Polymorphisms within these drug transporters result in inter-individual variation in drug response, with some patients no...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274788/ https://www.ncbi.nlm.nih.gov/pubmed/37333090 http://dx.doi.org/10.1101/2023.06.06.543963 |
_version_ | 1785059794895241216 |
---|---|
author | Yee, Sook Wah Macdonald, Christian Mitrovic, Darko Zhou, Xujia Koleske, Megan L. Yang, Jia Silva, Dina Buitrago Grimes, Patrick Rockefeller Trinidad, Donovan More, Swati S. Kachuri, Linda Witte, John S. Delemotte, Lucie Giacomini, Kathleen M. Coyote-Maestas, Willow |
author_facet | Yee, Sook Wah Macdonald, Christian Mitrovic, Darko Zhou, Xujia Koleske, Megan L. Yang, Jia Silva, Dina Buitrago Grimes, Patrick Rockefeller Trinidad, Donovan More, Swati S. Kachuri, Linda Witte, John S. Delemotte, Lucie Giacomini, Kathleen M. Coyote-Maestas, Willow |
author_sort | Yee, Sook Wah |
collection | PubMed |
description | Membrane transporters play a fundamental role in the tissue distribution of endogenous compounds and xenobiotics and are major determinants of efficacy and side effects profiles. Polymorphisms within these drug transporters result in inter-individual variation in drug response, with some patients not responding to the recommended dosage of drug whereas others experience catastrophic side effects. For example, variants within the major hepatic Human organic cation transporter OCT1 (SLC22A1) can change endogenous organic cations and many prescription drug levels. To understand how variants mechanistically impact drug uptake, we systematically study how all known and possible single missense and single amino acid deletion variants impact expression and substrate uptake of OCT1. We find that human variants primarily disrupt function via folding rather than substrate uptake. Our study revealed that the major determinants of folding reside in the first 300 amino acids, including the first 6 transmembrane domains and the extracellular domain (ECD) with a stabilizing and highly conserved stabilizing helical motif making key interactions between the ECD and transmembrane domains. Using the functional data combined with computational approaches, we determine and validate a structure-function model of OCT1s conformational ensemble without experimental structures. Using this model and molecular dynamic simulations of key mutants, we determine biophysical mechanisms for how specific human variants alter transport phenotypes. We identify differences in frequencies of reduced function alleles across populations with East Asians vs European populations having the lowest and highest frequency of reduced function variants, respectively. Mining human population databases reveals that reduced function alleles of OCT1 identified in this study associate significantly with high LDL cholesterol levels. Our general approach broadly applied could transform the landscape of precision medicine by producing a mechanistic basis for understanding the effects of human mutations on disease and drug response. |
format | Online Article Text |
id | pubmed-10274788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-102747882023-06-17 The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics Yee, Sook Wah Macdonald, Christian Mitrovic, Darko Zhou, Xujia Koleske, Megan L. Yang, Jia Silva, Dina Buitrago Grimes, Patrick Rockefeller Trinidad, Donovan More, Swati S. Kachuri, Linda Witte, John S. Delemotte, Lucie Giacomini, Kathleen M. Coyote-Maestas, Willow bioRxiv Article Membrane transporters play a fundamental role in the tissue distribution of endogenous compounds and xenobiotics and are major determinants of efficacy and side effects profiles. Polymorphisms within these drug transporters result in inter-individual variation in drug response, with some patients not responding to the recommended dosage of drug whereas others experience catastrophic side effects. For example, variants within the major hepatic Human organic cation transporter OCT1 (SLC22A1) can change endogenous organic cations and many prescription drug levels. To understand how variants mechanistically impact drug uptake, we systematically study how all known and possible single missense and single amino acid deletion variants impact expression and substrate uptake of OCT1. We find that human variants primarily disrupt function via folding rather than substrate uptake. Our study revealed that the major determinants of folding reside in the first 300 amino acids, including the first 6 transmembrane domains and the extracellular domain (ECD) with a stabilizing and highly conserved stabilizing helical motif making key interactions between the ECD and transmembrane domains. Using the functional data combined with computational approaches, we determine and validate a structure-function model of OCT1s conformational ensemble without experimental structures. Using this model and molecular dynamic simulations of key mutants, we determine biophysical mechanisms for how specific human variants alter transport phenotypes. We identify differences in frequencies of reduced function alleles across populations with East Asians vs European populations having the lowest and highest frequency of reduced function variants, respectively. Mining human population databases reveals that reduced function alleles of OCT1 identified in this study associate significantly with high LDL cholesterol levels. Our general approach broadly applied could transform the landscape of precision medicine by producing a mechanistic basis for understanding the effects of human mutations on disease and drug response. Cold Spring Harbor Laboratory 2023-06-07 /pmc/articles/PMC10274788/ /pubmed/37333090 http://dx.doi.org/10.1101/2023.06.06.543963 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Yee, Sook Wah Macdonald, Christian Mitrovic, Darko Zhou, Xujia Koleske, Megan L. Yang, Jia Silva, Dina Buitrago Grimes, Patrick Rockefeller Trinidad, Donovan More, Swati S. Kachuri, Linda Witte, John S. Delemotte, Lucie Giacomini, Kathleen M. Coyote-Maestas, Willow The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics |
title | The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics |
title_full | The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics |
title_fullStr | The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics |
title_full_unstemmed | The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics |
title_short | The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics |
title_sort | full spectrum of oct1 (slc22a1) mutations bridges transporter biophysics to drug pharmacogenomics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274788/ https://www.ncbi.nlm.nih.gov/pubmed/37333090 http://dx.doi.org/10.1101/2023.06.06.543963 |
work_keys_str_mv | AT yeesookwah thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT macdonaldchristian thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT mitrovicdarko thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT zhouxujia thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT koleskemeganl thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT yangjia thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT silvadinabuitrago thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT grimespatrickrockefeller thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT trinidaddonovan thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT moreswatis thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT kachurilinda thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT wittejohns thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT delemottelucie thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT giacominikathleenm thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT coyotemaestaswillow thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT yeesookwah fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT macdonaldchristian fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT mitrovicdarko fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT zhouxujia fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT koleskemeganl fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT yangjia fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT silvadinabuitrago fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT grimespatrickrockefeller fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT trinidaddonovan fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT moreswatis fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT kachurilinda fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT wittejohns fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT delemottelucie fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT giacominikathleenm fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics AT coyotemaestaswillow fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics |